The Evolution: From Private Diagnostic Labs to Public Arenas For years, the longevity narrative belonged almost exclusively to clinical diagnostics, pharmaceutical interventions, and quiet metabolic retreats. Millions were poured into measuring VO_2 max, muscle mass retention, and baseline cardiovascular health inside private labs. Then came Hyrox—and brought the diagnostics out of the clinic and into the arena.

The border between community endurance and ultra-luxury portfolios has officially dissolved. LVMH Capital, operating through its premier consumer-focused private equity vehicle L Catterton, has entered advanced exclusive negotiations to acquire a dominant majority stake in the global fitness racing phenomenon, HYROX. The deal, which negotiates terms with Switzerland-based sports marketing and rights giant Infront Sports & Media AG, commands a striking market valuation floor b

When L Catterton, the private equity fund backed by LVMH and Groupe Arnault, invested up to US$5 million in WTHN, the New York brand modernizing Traditional Chinese Medicine (TCM), they were not merely diversifying a portfolio. They were signaling the next era of luxury: East-meets-West longevity.

L Catterton, the private equity fund backed by LVMH and Groupe Arnault, has invested up to US$5 million in WTHN, the New York-based brand that modernises Traditional Chinese Medicine (TCM) through a clean, design-led luxury model.